Last reviewed · How we verify

NCT06615167

Confirmatory Clinical Trial for Verifying the Efficacy and Safety of 'ALZGUARD' as a Digital Dementia Diagnostic Aid-Tool for the Diagnosis of the Major Neurocognitive Disorders

Recruiting now NA Last updated 26 September 2024
What this trial tests

NA trial testing ALZGUARD in Dementia in 122 participants. Currently enrolling.

Timeline
12 September 2024
Primary endpoint
30 April 2025
30 April 2025

Quick facts

Lead sponsorHAII corp.ltd
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment122
Start date12 September 2024
Primary completion30 April 2025
Estimated completion30 April 2025
Sites3 locations across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

HAII corp.ltd

Who can join

Adults 55 to 85, any sex, with Dementia or Major Neurocognitive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evalute the efficacy of ALZGUARD, a smartphone-based digital therapeutic(DTx), in comparison to diagnosis by medical doctors, as weel as to assess the safety of the application.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Dementia

Currently open trials in the same condition.

Other HAII corp.ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06615167.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing